ARCHIVES

NCCN’s First Physician CEO: Robert Carlson Pledges Broader Research and Policy Agenda

This article is from The Cancer Letter archive.

Vol. 38 No. 37 | October 5, 2012

Download PDF Visit The Full Archive

Related Articles

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

May 7, 2004

Circulating Tumor Cells Predict Treatment Resistance In Study Of Metastatic Breast Cancer

August 30, 2013

Coffee, Soft Drinks Have Little Association With Colon Cancer

May 28, 2010

Obey Says NCI “Must Do Better,” Response Dispute GAO Conclusion

August 8, 1980

HHS Awards $85 Million For Research to Eliminate Health Disparities

November 15, 2002

Congress Asked To Equalize Cuts, Add $20 million For Centers

April 25, 1980